Search | Clinical Trials Finder

Conditions: Male Osteoporosis
Interventions: Teriparatide or human parathyroid hormone (PTH) 1-34, Cinacalcet, placebo tablet, Calcium citrate tablet, Vitamin D3; Drug · Dietary Supplement
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years to 85 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Osteoporosis
Interventions: placebo, ALX1-11; Drug
Lead sponsor: Shire; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 2,532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 107
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 95 more

Conditions: Adipose Tissue, Brown, Adipose Tissue, Obesity
Interventions: Fat biopsy, Blood sampling, Blood sample for DNA analysis; Procedure · Diagnostic Test · Genetic
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoporosis
Interventions: Parathyroid hormone-related protein or ''PTHrP''; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 50 Years to 75 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Osteopenia, Osteoporosis
Interventions: Teriparatide, Placebo teriparatide; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bangor, Maine

Conditions: Thyroid; Wound, Parathyroid Diseases, Surgical Incision, Incision
Interventions: Amnioeffect; Other
Lead sponsor: Sarasota Memorial Health Care System; Other
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sarasota, Florida

Conditions: Hypoparathyroidism
Interventions: NPSP558; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 14
States / cities: Lakewood, California • Jacksonville, Florida • Chicago, Illinois + 11 more

Conditions: Lumbar Spondylosis, Lumbar Spondylolisthesis, Adult Degenerative Lumbar Scoliosis
Interventions: teriparatide, Placebo; Biological
Lead sponsor: Shane Burch; Other
Eligibility: 60 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Osteoporosis
Interventions: Human parathyroid hormone [hPTH-(1-34)], alendronate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years to 85 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypoparathyroidism
Interventions: Placebo, NPSP558; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 19
States / cities: Scottsdale, Arizona • Lakewood, California • Orange, California + 16 more

Conditions: Hypoparathyroidism, Hypocalcemia, Autoimmune Polyendocrine Syndrome Type 1, Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Interventions: Synthetic Human Parathyroid Hormone 1-34 pump; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 7 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome, Complete Atypical DiGeorge Syndrome
Interventions: Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw, Rabbit anti-thymocyte globulin, Cyclosporine, Tacrolimus, Methylprednisolone or Prednisolone, Daclizumab, Mycophenolate mofetil; Biological · Other · Procedure + 1 more
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: Not listed
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypoparathyroidism
Interventions: 25mcg rhPTH(1-84), 50mcg rhPTH(1-84), 100mcg rhPTH(1-84); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 10
States / cities: North Hollywood, California • Indianapolis, Indiana • Lexington, Kentucky + 7 more

Conditions: Hypoparathyroidism
Interventions: NPSP558; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 12
States / cities: Lakewood, California • Chicago, Illinois • Indianapolis, Indiana + 9 more

Conditions: Osteoporosis
Interventions: human parathyroid hormone; Drug
Lead sponsor: Columbia University; Other
Eligibility: 29 Years to 67 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: DiGeorge Anomaly, DiGeorge Syndrome, Complete DiGeorge Anomaly, Complete DiGeorge Syndrome
Interventions: Cultured Thymus Tissue Implantation (CTTI), Cultured Thymus Tissue Implantation with Parathyroid Transplantation; Biological · Other
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: Not listed
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Volunteers
Interventions: rhPTH(1-84); Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Knee Osteoarthritis, Cartilage Degeneration
Interventions: Teriparatide, Placebo; Drug
Lead sponsor: Christopher Ritchlin; Other
Eligibility: 40 Years to 60 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hypoparathyroidism
Interventions: rhPTH (1-84), Placebo; Biological
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Chicago, Illinois • Detroit, Michigan • Rochester, Minnesota + 3 more

Conditions: Hypoparathyroidism
Interventions: Synthetic Human Parathyroid Hormone 1-34, Calcitriol & Calcium; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 17 Years to 69 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoporosis
Interventions: PTH/Calcium, PTH/placebo, placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 17
States / cities: Rancho Cucamonga, California • Lake Worth, Florida • Coeur d'Alene, Idaho + 14 more

Conditions: Transplantation, Stem Cell
Interventions: Ronacaleret 100 mg, Ronacaleret 400 mg, Plerixafor; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hypoparathyroidism
Interventions: PTH1-84 in parent study; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteopetrosis
Interventions: rhPTH; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Novel Combination Therapy for Osteoporosis in Men

TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis

The Physiology of Human Brown Adipose Tissue

PTHrP and Osteoporosis

Once Weekly Parathyroid Hormone for Osteoporosis

Comparing the Impact of AMNIOEFFECT Application vs Standard of Care on Post-Operative Healing in Patients Who Have Undergone Thyroid and Parathyroid Surgery Via the Transcutaneous Approach

A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)

Use of Forteo (Teriparatide) in Posterolateral Lumbar Spine Fusion

Alendronate and/or Parathyroid Hormone for Osteoporosis

Use of NPSP558 in the Treatment of Hypoparathyroidism

Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism

Phase I/II Thymus Transplantation With Immunosuppression #950

Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism

Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)

Randomized Study of Human Parathyroid Hormone in Middle-Aged Men With Idiopathic Osteoporosis

Thymus Transplantation Dose in DiGeorge #932

A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults

Teriparatide as a Chondroregenerative Therapy in OA

A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)

Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34

Calcium Supplementation in Postmenopausal Women

Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)

ADD-ON Study to Existing Hypoparathyroidism Studies

rhPTH Therapy for Low Turnover Bone Fragility